Compare BLBD & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | ANIP |
|---|---|---|
| Founded | 1927 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2013 | 1999 |
| Metric | BLBD | ANIP |
|---|---|---|
| Price | $70.65 | $79.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | $68.00 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 408.8K | 244.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 22.78 | ★ 419.23 |
| EPS | ★ 1.84 | 1.28 |
| Revenue | ★ $1,480,099,000.00 | $206,547,000.00 |
| Revenue This Year | $5.87 | $21.01 |
| Revenue Next Year | $6.83 | $17.59 |
| P/E Ratio | ★ $41.33 | $61.23 |
| Revenue Growth | ★ 9.87 | 2.47 |
| 52 Week Low | $42.95 | $62.61 |
| 52 Week High | $83.39 | $99.50 |
| Indicator | BLBD | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 48.73 |
| Support Level | $60.73 | $79.69 |
| Resistance Level | $73.75 | $83.66 |
| Average True Range (ATR) | 2.82 | 2.39 |
| MACD | -0.81 | -0.32 |
| Stochastic Oscillator | 16.52 | 39.84 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.